Industry Statements Regarding COVID-19 Impact

INSULIN PUMPS AND CGM DEVICES

1. **Tandem** anticipates no shortages related to pumps or supplies. Tandem has also included a reminder about cleaning your pump: https://www.tandemdiabetes.com/blog/post/general/2020/03/11/no-covid-19-interruption-to-supplies-access

2. **Medtronic** has updated their website with COVID-19 information and resources. A link to their on-line shop for supplies is also included: https://www.medtronicdiabetes.com/customer-support/product-and-service-updates/nd26

3. **Insulet** anticipates no supply shortage. Telehealth consult continues to be supported through Insulet Provided Glooko and virtual training sessions and clinic days are underway: https://www.myomnipod.com/coronavirus

4. **Dexcom** anticipates no supply shortage: https://www.dexcom.com/coronavirus

5. **Senseonics** anticipates no supply shortage: https://www.senseonics.com/products/product-alerts. **UPDATE 3/26:** Senseonics Holdings, Inc. suspended commercial sales of its Eversense continuous glucose monitor (CGM) in the United States. In an effort to reduce overall costs, Senseonics is electing to stop selling to new patients and practices but will continue to distribute to current Eversense CGM users.

INSULIN COMPANIES

6. **Lilly** anticipates no supply shortages. They offer specific phone numbers to call with questions during this time: https://www.lilly.com/news/stories/coronavirus-covid19-global-response


9. **Mannkind** has posted this statement “MannKind does not anticipate that the supply of its inhalable insulin Afrezza® (insulin human) Inhalation Powder will be affected by the coronavirus.” https://www.mannkindcorp.com/coronavirus-update.html

11. **BD (Becton Dickinson)** has posted the following statement **“BD continues to meet current demand for the vast majority of our products and does not currently expect disruptions to product availability due to production shortages related to COVID-19.** However, we are seeing high demand in select product categories because of a prolonged flu season and the coronavirus pandemic. We are closely monitoring this dynamic situation and will keep customers informed on any meaningful changes to product availability as the situation evolves.” [https://www.bd.com/en-us/support/alerts-and-notices/bd-statement-on-coronavirus](https://www.bd.com/en-us/support/alerts-and-notices/bd-statement-on-coronavirus)


13. **Ascensia** has posted this statement “At present, there appears to be no immediate impact on the supply of our test strips and meters, and we do not anticipate any short-term issues related to the supply of these products due to COVID-19.” [https://www.ascensia.com/coronavirus-information-center/](https://www.ascensia.com/coronavirus-information-center/)


15. **Merck** has posted the following statement “While supply and demand vary by product, there are not any current impacts from COVID-19 on the production and supply of our medicines and vaccines for the U.S. However, we are working to assess an increase in demand for our pneumococcal vaccine.” [https://www.merck.com/about/featured-stories/how-we-are-responding-to-the-global-pandemic-COVID-19.html](https://www.merck.com/about/featured-stories/how-we-are-responding-to-the-global-pandemic-COVID-19.html)


17. **Regeneron** has posted the following statement “Given the current pandemic situation, we are paying additional attention to help secure the continued availability of our medicines both commercially and for clinical studies.” [https://www.regeneron.com/covid19](https://www.regeneron.com/covid19)

18. **Bristol Myers Squibb** has posted the following statement “At this time we do not anticipate disruptions to the supply of our medicines for patients due to COVID-19.” [https://www.bms.com/about-us/responsibility/coronavirus-updates.html](https://www.bms.com/about-us/responsibility/coronavirus-updates.html)